Alnylam Pharmaceuticals, Inc. (ALNY)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
234.03 USD
+9.56
(4.259%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 235.20 +1.17 (0.500%) ⇧ (Oct. 15, 2026, 4:08 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 1:43 a.m. EDT
Alnylam's long-term fundamentals are elite, boasting a 96% return on equity and explosive 67% revenue growth while trading at a forward P/E of just 18.7x. The balance sheet is fortified with net cash, and analysts see substantial upside to $371, implying a 55% gain from current levels. While the stock is currently trading below its 50-day and 200-day moving averages, creating a short-term headwind, the underlying business quality is exceptional. Options flow reflects this tension, with traders hedging downside risks while aggressively betting on upside potential at higher strikes. For investors willing to ride out the technical correction, the data supports a top-tier buy. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.109415 |
| AutoARIMA | 0.122887 |
| AutoETS | 0.128713 |
| MSTL | 0.130863 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.12 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.777 |
| Excess Kurtosis | -0.51 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 220.623 |
| Revenue per Share | 36.245 |
| Market Cap | 31,315,347,456 |
| Trailing P/E | 39.47 |
| Forward P/E | 18.76 |
| Beta | 0.27 |
| Profit Margins | 16.13% |
| Website | https://www.alnylam.com |
As of Oct. 10, 2026, 1:43 a.m. EDT: Speculators are positioning for significant volatility with a bullish skew at higher strikes (300-560 calls) versus defensive hedges at lower levels (150-210 puts). Implied volatility is elevated at deep ITM strikes, indicating anticipation of large moves in either direction, though call volume at distant expirations suggests a preference for upside participation.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.51412797 |
| Address1 | 675 West Kendall Street |
| Address2 | Henri A. Termeer Square |
| All Time High | 495.55 |
| All Time Low | 3.65 |
| Ask | 250.08 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 1,249,320 |
| Average Daily Volume3 Month | 1,721,157 |
| Average Volume | 1,721,157 |
| Average Volume10Days | 1,249,320 |
| Beta | 0.269 |
| Bid | 229.71 |
| Bid Size | 1 |
| Board Risk | 2 |
| Book Value | 10.125 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 234.03 |
| Current Ratio | 3.055 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 234.3 |
| Day Low | 228.12 |
| Debt To Equity | 220.623 |
| Display Name | Alnylam Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,793,304,000 |
| Earnings Call Timestamp Start | 1,793,304,000 |
| Earnings Timestamp | 1,793,277,000 |
| Earnings Timestamp End | 1,793,277,000 |
| Earnings Timestamp Start | 1,793,277,000 |
| Ebitda | 1,054,537,984 |
| Ebitda Margins | 0.2195 |
| Enterprise To Ebitda | 29.392 |
| Enterprise To Revenue | 6.452 |
| Enterprise Value | 30,994,690,048 |
| Eps Current Year | 8.93836 |
| Eps Forward | 12.47744 |
| Eps Trailing Twelve Months | 5.93 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 617 551 8101 |
| Fifty Day Average | 238.0998 |
| Fifty Day Average Change | -4.0697937 |
| Fifty Day Average Change Percent | -0.017092807 |
| Fifty Two Week Change Percent | -51.412796 |
| Fifty Two Week High | 495.55 |
| Fifty Two Week High Change | -261.52 |
| Fifty Two Week High Change Percent | -0.52773684 |
| Fifty Two Week Low | 197.81 |
| Fifty Two Week Low Change | 36.22 |
| Fifty Two Week Low Change Percent | 0.183105 |
| Fifty Two Week Range | 197.81 - 495.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,086,096,600,000 |
| Float Shares | 133,224,372 |
| Forward Eps | 12.47744 |
| Forward P E | 18.756252 |
| Free Cashflow | 271,544,256 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,500 |
| Fullday Change | 11.110001 |
| Fullday Change Percent | 4.9494367 |
| Fullday Price | 234.03 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.79654 |
| Gross Profits | 3,826,732,032 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00182 |
| Held Percent Institutions | 1.01699 |
| Implied Shares Outstanding | 133,809,118 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Alnylam Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 31,315,347,456 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_2796659 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 774,710,976 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 32,985,285,678 |
| Number Of Analyst Opinions | 27 |
| Open | 230.0 |
| Operating Cashflow | 911,812,992 |
| Operating Margins | 0.17928 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.29 |
| Phone | 617 551 8200 |
| Post Market Change | 1.1699982 |
| Post Market Change Percent | 0.49993512 |
| Post Market Price | 235.2 |
| Post Market Time | 1,792,094,888 |
| Previous Close | 224.47 |
| Price Eps Current Year | 26.182655 |
| Price Hint | 2 |
| Price To Book | 23.114075 |
| Price To Sales Trailing12 Months | 6.5183516 |
| Profit Margins | 0.16126 |
| Quick Ratio | 2.791 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | 9.56 |
| Regular Market Change Percent | 4.25892 |
| Regular Market Day High | 234.3 |
| Regular Market Day Low | 228.12 |
| Regular Market Day Range | 228.12 - 234.3 |
| Regular Market Open | 230.0 |
| Regular Market Previous Close | 224.47 |
| Regular Market Price | 234.03 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 1,257,395 |
| Return On Assets | 0.123430006 |
| Return On Equity | 0.96555 |
| Revenue Growth | 0.669 |
| Revenue Per Share | 36.245 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 133,809,118 |
| Shares Percent Shares Out | 0.057600003 |
| Shares Short | 7,711,495 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 6,340,087 |
| Short Name | Alnylam Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.076799996 |
| Short Ratio | 5.17 |
| Source Interval | 15 |
| State | MA |
| Symbol | ALNY |
| Target High Price | 536.0 |
| Target Low Price | 250.0 |
| Target Mean Price | 368.71112 |
| Target Median Price | 350.0 |
| Total Cash | 3,308,146,944 |
| Total Cash Per Share | 24.723 |
| Total Debt | 2,987,489,024 |
| Total Revenue | 4,804,182,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 5.93 |
| Trailing P E | 39.46543 |
| Trailing Peg Ratio | 0.3248 |
| Triggerable | 1 |
| Two Hundred Day Average | 295.12436 |
| Two Hundred Day Average Change | -61.09436 |
| Two Hundred Day Average Change Percent | -0.20701227 |
| Type Disp | Equity |
| Volume | 1,257,395 |
| Website | https://www.alnylam.com |
| Zip | 2,142 |